Evidence map›Paper›PMID 41102295›Full record

ArticleScientific reports2025

Bone regeneration induced by a novel quercetin/a-CSH/n-HA composite in critical size tibia defect of rats with osteoporosis.

Mingliang Ren, Yunjie Yang, Kun Chen, Gang Mei, Wei Zeng, Jinfu Wei, Qian Chen

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mingliang Ren *Department of Orthopaedics, The Sixth Afffliated Hospital, South China University of Technology, No.120, Guidan Rd, Foshan, 528200, China. lyrenml@scut.edu.cn.
Yunjie Yang *Department of Pediatric Surgery, The Sixth Afffliated Hospital, South China University of Technology, Foshan, 528200, China.
Kun ChenDepartment of Orthopaedics, The Sixth Afffliated Hospital, South China University of Technology, No.120, Guidan Rd, Foshan, 528200, China.
Gang MeiDepartment of Orthopaedics, The Sixth Afffliated Hospital, South China University of Technology, No.120, Guidan Rd, Foshan, 528200, China.
Wei ZengDepartment of Orthopaedics, The Sixth Afffliated Hospital, South China University of Technology, No.120, Guidan Rd, Foshan, 528200, China.
Jinfu WeiDepartment of Orthopaedics, The Sixth Afffliated Hospital, South China University of Technology, No.120, Guidan Rd, Foshan, 528200, China.
Qian ChenDepartment of Orthopaedics, The Sixth Afffliated Hospital, South China University of Technology, No.120, Guidan Rd, Foshan, 528200, China.

Funding

National Natural Science Foundation of China 8227091135
6 · The paper itself

Abstract

Bone defects in the presence of osteoporosis present a significant clinical challenge. To address this, we sought to engineer a novel artificial bone substitute exhibiting excellent biocompatibility, osteoconductivity, osteoinduction, anti-aging, and anti-osteoporotic capabilities for enhanced bone regeneration. This project introduces an innovative Q-α-CSH/n-HA composite, synthesized by incorporating Quercetin into alpha-calcium sulfate hemihydrate/nano-hydroxyapatite (α-CSH/n-HA). Q-α-CSH/n-HA composites were fabricated via direct mixing, incorporating Quercetin at concentrations of 0%, 0.5%, 1.5%, and 3%. Physicochemical characteristics were analyzed through Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). The osteoinductive potential and efficacy in promoting bone defect repair were investigated in a critical tibial defect model using 40 one-year-old osteoporotic female SD rats, randomly allocated to four experimental groups. Outcomes, including bone defect repair, material degradation, new bone morphology, and expression of RunX2, OSX, and OCN, were assessed using X-ray, micro-CT, and comprehensive histopathological staining (H&E, Goldner, Safranin O, and immunofluorescence). As the proportion of quercetin increased within the composite, we observed an enrichment in elemental composition and a pronounced elevation in both in vitro and in vivo biological activity of the Q-α-CSH/n-HA complex, despite comparable morphological features as assessed by SEM. Radiographic (X-ray) and micro-CT analyses consistently demonstrated that quercetin-supplemented composite groups significantly enhanced bone defect repair and neobone formation. Complementary histopathological examinations (H&E, Goldner, and Safranin O staining) corroborated these findings, indicating that quercetin significantly augmented new bone generation and accelerated composite biodegradation. Immunofluorescence confirmed that quercetin markedly increased the abundance of RUNX2-, OSX-, and OCN-positive cells. Moreover, CFU assays revealed that the 3% quercetin group yielded significantly superior results compared to the control. The Q-α-CSH/n-HA composite possesses excellent in vitro biocompatibility, osteoconductivity, and osteoinduction. Critically, in vivo studies demonstrated its significant anti-aging, anti-osteoporotic, and overall reparative effects during bone reconstruction. We propose that the mechanism involves a synergistic action between quercetin and calcium ions, which collectively promote the proliferation, migration, recruitment, and osteogenic differentiation of BMSCs. Consequently, the Q-α-CSH/n-HA composite stands as a highly promising artificial bone graft for accelerating bone regeneration, especially pertinent for individuals suffering from osteoporosis.

Indexed as

Bone RegenerationBone SubstitutesCalcium SulfateDurapatiteOsteoporosisQuercetinTibiaAnimalsDisease Models, AnimalFemaleOsteogenesisRatsRats, Sprague-DawleyX-Ray MicrotomographyBone SubstitutesCalcium SulfateDurapatiteQuercetinAnti-osteoporosisArtificial bone graftCritical-size defectEnhanced bone formationNano-hydroxyapatiteQuercetin

Identifiers

PMID41102295
PMCPMC12533126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.